IDMF is a derivative of dimethyl fumarate (DMF) with a unique therapeutic potential at the intersection of psoriasis and multiple sclerosis. Here, we demonstrate that it compares favorably with DMF and its other derivatives, such as Diroximel, in the zebrafish, microglia, and lymphocyte models.
Yulin He+5 more
wiley +1 more source
Cost-Effectiveness of Universal Screen-and-Treat Strategies for Reducing Morbidity and Mortality of Chronic Hepatitis B in a High-Endemicity City. [PDF]
Wong NS, Chan DP, Wong GL, Lee SS.
europepmc +1 more source
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy+14 more
wiley +1 more source
Clinical presentation and treatment outcomes of extrapulmonary nontuberculous mycobacterial infections with rapid and slow growth rates in Cali, Colombia. [PDF]
Parra-Villamil JM+5 more
europepmc +1 more source
A potential tumor suppressor role of PLK2 in glioblastoma
PLK2 was consistently downregulated in GBM tissues. Overexpression of PLK2 in GBM cell lines U87MG and U251 reduced their tumorigenic potential and enhanced cell cycle arrest and apoptosis. Suggesting that PLK2 overexpression could potentially be leveraged as a therapeutic strategy to inhibit tumor progression and enhance apoptosis, providing new ...
Xiangping Xia+5 more
wiley +1 more source
A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment. [PDF]
Deodhar A+10 more
europepmc +1 more source
Identification of inhibitors of the Salmonella FraB deglycase, a drug target
A high‐throughput screen was used to identify inhibitors of Salmonella FraB, a drug target. Characterization of top hits (identified after an additional counter screen) revealed that some triazolidines, thiadiazolidines, and triazolothiadiazoles are mixed‐type inhibitors of FraB.
Jamison D. Law+6 more
wiley +1 more source
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial. [PDF]
Bian D+25 more
europepmc +1 more source
A case with systemic juvenile idiopathic arthritis treated with tofacitinib and rapamycin. [PDF]
Cam V, Sag E, Bilginer Y, Ozen S.
europepmc +1 more source